MTNB
Matinas BioPharma Holdings, Inc.
MTNB
(1.0)0,62 USD
-114.49% ROA
-120.5% ROE
-35.81x PER
16.503.693,00 USD
16.97% DER
0% Yield
2090.51% NPM
Matinas BioPharma Holdings, Inc. Stock Analysis
Matinas BioPharma Holdings, Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a low debt to equity ratio (14%), which means it has a small amount of debt compared to the ownership it holds |
|
| 2 |
PBV
The stock's PBV ratio (1.83x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns. |
|
| 3 |
Graham Number
The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option. |
|
| 4 |
ROE
The stock's ROE indicates a negative return (-50.08%) on shareholders' equity, suggesting poor financial performance. |
|
| 5 |
ROA
The stock's ROA (-57.27%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns. |
|
| 6 |
Revenue Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 7 |
Net Profit Growth
Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors. |
|
| 8 |
Assets Growth
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice. |
|
| 9 |
Dividend Growth
The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity. |
|
| 10 |
Dividend
The company's lack of dividends in the past three years may concern investors seeking regular income. |
|
| 11 |
Buffet Intrinsic Value
Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value. |
Matinas BioPharma Holdings, Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Sell |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Hold |
Matinas BioPharma Holdings, Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2012 | 0 | |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 194.494 | 100% |
| 2016 | 0 | 0% |
| 2017 | 149.687 | 100% |
| 2018 | 119.750 | -25% |
| 2019 | 90.000 | -33.06% |
| 2020 | 158.333 | 43.16% |
| 2021 | 33.333 | -375% |
| 2022 | 3.188.000 | 98.95% |
| 2023 | 0 | 0% |
| 2023 | 1.096.000 | 100% |
| 2024 | 0 | 0% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2012 | 78.846 | |
| 2013 | 1.761.486 | 95.52% |
| 2014 | 5.175.520 | 65.97% |
| 2015 | 5.292.193 | 2.2% |
| 2016 | 3.947.644 | -34.06% |
| 2017 | 9.010.499 | 56.19% |
| 2018 | 6.787.474 | -32.75% |
| 2019 | 11.235.000 | 39.59% |
| 2020 | 14.358.918 | 21.76% |
| 2021 | 14.583.283 | 1.54% |
| 2022 | 16.678.000 | 12.56% |
| 2023 | 13.180.000 | -26.54% |
| 2023 | 14.489.000 | 9.03% |
| 2024 | 13.484.000 | -7.45% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2012 | 37.229 | |
| 2013 | 1.950.953 | 98.09% |
| 2014 | 5.289.479 | 63.12% |
| 2015 | 4.813.800 | -9.88% |
| 2016 | 4.309.489 | -11.7% |
| 2017 | 7.641.592 | 43.6% |
| 2018 | 7.978.821 | 4.23% |
| 2019 | 7.776.000 | -2.61% |
| 2020 | 10.005.967 | 22.29% |
| 2021 | 10.184.805 | 1.76% |
| 2022 | 11.100.000 | 8.25% |
| 2023 | 11.356.000 | 2.25% |
| 2023 | 10.373.000 | -9.48% |
| 2024 | 9.872.000 | -5.07% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2012 | 0 | |
| 2013 | -3.711.308 | 100% |
| 2014 | -10.692.545 | 65.29% |
| 2015 | -10.624.469 | -0.64% |
| 2016 | -8.879.390 | -19.65% |
| 2017 | -17.038.726 | 47.89% |
| 2018 | -14.428.237 | -18.09% |
| 2019 | -19.928.000 | 27.6% |
| 2020 | -25.279.841 | 21.17% |
| 2021 | -26.063.225 | 3.01% |
| 2022 | -28.081.000 | 7.19% |
| 2023 | -24.536.000 | -14.45% |
| 2023 | -22.825.000 | -7.5% |
| 2024 | -22.392.000 | -1.93% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2012 | 0 | |
| 2013 | 0 | 0% |
| 2014 | -5.175.520 | 100% |
| 2015 | -5.097.699 | -1.53% |
| 2016 | -52.644 | -9583.34% |
| 2017 | -8.860.812 | 99.41% |
| 2018 | -6.667.724 | -32.89% |
| 2019 | -11.144.548 | 40.17% |
| 2020 | -14.200.585 | 21.52% |
| 2021 | -748.158 | -1798.07% |
| 2022 | -13.490.000 | 94.45% |
| 2023 | 0 | 0% |
| 2023 | 155.000 | 100% |
| 2024 | -964.000 | 116.08% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2012 | -116.075 | |
| 2013 | -3.713.127 | 96.87% |
| 2014 | -10.221.045 | 63.67% |
| 2015 | -9.135.400 | -11.88% |
| 2016 | -7.598.737 | -20.22% |
| 2017 | -15.486.489 | 50.93% |
| 2018 | -14.083.073 | -9.97% |
| 2019 | -15.585.184 | 9.64% |
| 2020 | -20.598.962 | 24.34% |
| 2021 | -21.173.454 | 2.71% |
| 2022 | -13.015.000 | -62.69% |
| 2023 | -24.220.000 | 46.26% |
| 2023 | -22.942.000 | -5.57% |
| 2024 | -22.876.000 | -0.29% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2012 | 0 | |
| 2013 | 0 | 0% |
| 2014 | 0 | 0% |
| 2015 | 0 | 0% |
| 2016 | 0 | 0% |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 0 | 0% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
| 2023 | 0 | 0% |
| 2024 | 0 | 0% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2012 | -57.264 | |
| 2013 | -3.082.025 | 98.14% |
| 2014 | -8.249.715 | 62.64% |
| 2015 | -7.890.582 | -4.55% |
| 2016 | -6.118.723 | -28.96% |
| 2017 | -12.401.617 | 50.66% |
| 2018 | -10.857.125 | -14.23% |
| 2019 | -14.497.670 | 25.11% |
| 2020 | -17.373.585 | 16.55% |
| 2021 | -15.483.835 | -12.2% |
| 2022 | -20.048.000 | 22.77% |
| 2023 | -4.435.000 | -352.04% |
| 2023 | -15.496.000 | 71.38% |
| 2024 | -3.106.000 | -398.91% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2012 | -57.264 | |
| 2013 | -2.987.837 | 98.08% |
| 2014 | -7.961.196 | 62.47% |
| 2015 | -7.814.403 | -1.88% |
| 2016 | -6.118.723 | -27.71% |
| 2017 | -11.459.437 | 46.61% |
| 2018 | -10.321.209 | -11.03% |
| 2019 | -14.092.066 | 26.76% |
| 2020 | -17.367.836 | 18.86% |
| 2021 | -15.223.455 | -14.09% |
| 2022 | -19.156.000 | 20.53% |
| 2023 | -4.419.000 | -333.49% |
| 2023 | -15.278.000 | 71.08% |
| 2024 | -3.106.000 | -391.89% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2012 | 0 | |
| 2013 | 94.188 | 100% |
| 2014 | 288.519 | 67.35% |
| 2015 | 76.179 | -278.74% |
| 2016 | 0 | 0% |
| 2017 | 942.180 | 100% |
| 2018 | 535.916 | -75.81% |
| 2019 | 405.604 | -32.13% |
| 2020 | 5.749 | -6955.21% |
| 2021 | 260.380 | 97.79% |
| 2022 | 892.000 | 70.81% |
| 2023 | 16.000 | -5475% |
| 2023 | 218.000 | 92.66% |
| 2024 | 0 | 0% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2012 | 339.937 | |
| 2013 | 10.474.788 | 96.75% |
| 2014 | 2.227.896 | -370.17% |
| 2015 | 6.072.403 | 63.31% |
| 2016 | 7.149.961 | 15.07% |
| 2017 | 10.681.965 | 33.07% |
| 2018 | 16.141.724 | 33.82% |
| 2019 | 33.051.000 | 51.16% |
| 2020 | 63.730.697 | 48.14% |
| 2021 | 52.493.058 | -21.41% |
| 2022 | 36.637.000 | -43.28% |
| 2023 | 19.246.000 | -90.36% |
| 2023 | 23.150.000 | 16.86% |
| 2024 | 19.103.000 | -21.19% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2012 | 424.364 | |
| 2013 | 11.333.756 | 96.26% |
| 2014 | 3.361.450 | -237.17% |
| 2015 | 8.406.078 | 60.01% |
| 2016 | 9.816.341 | 14.37% |
| 2017 | 14.423.692 | 31.94% |
| 2018 | 19.943.242 | 27.68% |
| 2019 | 40.240.000 | 50.44% |
| 2020 | 70.967.306 | 43.3% |
| 2021 | 61.326.074 | -15.72% |
| 2022 | 44.819.000 | -36.83% |
| 2023 | 65.578.000 | 31.66% |
| 2023 | 29.791.000 | -120.13% |
| 2024 | 24.365.000 | -22.27% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2012 | 84.427 | |
| 2013 | 858.968 | 90.17% |
| 2014 | 1.133.554 | 24.22% |
| 2015 | 2.333.675 | 51.43% |
| 2016 | 2.666.380 | 12.48% |
| 2017 | 3.741.727 | 28.74% |
| 2018 | 3.801.518 | 1.57% |
| 2019 | 7.189.000 | 47.12% |
| 2020 | 7.236.609 | 0.66% |
| 2021 | 8.833.016 | 18.07% |
| 2022 | 8.182.000 | -7.96% |
| 2023 | 46.332.000 | 82.34% |
| 2023 | 6.641.000 | -597.67% |
| 2024 | 5.262.000 | -26.21% |
Matinas BioPharma Holdings, Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- -0
- Net Income per Share
- -0.09
- Price to Earning Ratio
- -35.81x
- Price To Sales Ratio
- -15.06x
- POCF Ratio
- -45.9
- PFCF Ratio
- -0.92
- Price to Book Ratio
- 42.94
- EV to Sales
- -14.12
- EV Over EBITDA
- -0.67
- EV to Operating CashFlow
- -0.87
- EV to FreeCashFlow
- -0.87
- Earnings Yield
- -0.03
- FreeCashFlow Yield
- -1.08
- Market Cap
- 0,02 Bil.
- Enterprise Value
- 0,02 Bil.
- Graham Number
- 0.4
- Graham NetNet
- 0.04
Income Statement Metrics
- Net Income per Share
- -0.09
- Income Quality
- 0.78
- ROE
- -1.2
- Return On Assets
- -0.94
- Return On Capital Employed
- -1.08
- Net Income per EBT
- 1
- EBT Per Ebit
- 0.96
- Ebit per Revenue
- 21.68
- Effective Tax Rate
- -0.01
Margins
- Sales, General, & Administrative to Revenue
- -9.11
- Research & Developement to Revenue
- -12.57
- Stock Based Compensation to Revenue
- -4.06
- Gross Profit Margin
- 1.88
- Operating Profit Margin
- 21.68
- Pretax Profit Margin
- 20.91
- Net Profit Margin
- 20.91
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -0.07
- Free CashFlow per Share
- -0.07
- Capex to Operating CashFlow
- -0
- Capex to Revenue
- -0.01
- Capex to Depreciation
- 0.02
- Return on Invested Capital
- -1.08
- Return on Tangible Assets
- -1.14
- Days Sales Outstanding
- 0
- Days Payables Outstanding
- 90.58
- Days of Inventory on Hand
- 0
- Receivables Turnover
- 0
- Payables Turnover
- 4.03
- Inventory Turnover
- 0
- Capex per Share
- 0
Balance Sheet
- Cash per Share
- 0,06
- Book Value per Share
- 0,08
- Tangible Book Value per Share
- 0.06
- Shareholders Equity per Share
- 0.08
- Interest Debt per Share
- 0.01
- Debt to Equity
- 0.17
- Debt to Assets
- 0.13
- Net Debt to EBITDA
- 0.04
- Current Ratio
- 6.39
- Tangible Asset Value
- 0,01 Bil.
- Net Current Asset Value
- 0,01 Bil.
- Invested Capital
- 21773000
- Working Capital
- 0,01 Bil.
- Intangibles to Total Assets
- 0.18
- Average Receivables
- 0,00 Bil.
- Average Payables
- 0,00 Bil.
- Average Inventory
- 0
- Debt to Market Cap
- 0.2
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Matinas BioPharma Holdings, Inc. Profile
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
- CEO
- Mr. Jerome D. Jabbour J.D.
- Employee
- 32
- Address
-
1545 Route 206 South
Bedminster, 07921
Matinas BioPharma Holdings, Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Dr. Theresa Matkovits Ph.D. Chief Development Officer |
70 |
| 2 |
Mr. Frank Calamusa Executive Director and Head of Manufacturing & Supply Chain |
70 |
| 3 |
Mr. Keith A. Kucinski CPA, M.B.A. Chief Financial Officer |
70 |
| 4 |
Mr. Thomas J. Hoover M.B.A. Chief Business Officer |
70 |
| 5 |
Mr. Jerome D. Jabbour J.D. Co-Founder, Chief Executive Officer, President & Director |
70 |
| 6 |
Dr. Hui Liu M.B.A., Ph.D. Chief Technology Officer |
70 |
| 7 |
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer |
70 |
Matinas BioPharma Holdings, Inc. Competitors
